Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables - Other: 2013-2025

Historic Receivables - Other for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $18.3 million.

  • Theravance Biopharma's Receivables - Other rose 8.44% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 8.44%. This contributed to the annual value of $18.4 million for FY2024, which is 5.53% up from last year.
  • Latest data reveals that Theravance Biopharma reported Receivables - Other of $18.3 million as of Q3 2025, which was down 16.66% from $21.9 million recorded in Q2 2025.
  • Theravance Biopharma's Receivables - Other's 5-year high stood at $43.8 million during Q3 2021, with a 5-year trough of $12.3 million in Q1 2023.
  • Its 3-year average for Receivables - Other is $16.6 million, with a median of $16.8 million in 2024.
  • Data for Theravance Biopharma's Receivables - Other shows a peak YoY increase of 61.17% (in 2021) and a maximum YoY decrease of 73.86% (in 2021) over the last 5 years.
  • Over the past 5 years, Theravance Biopharma's Receivables - Other (Quarterly) stood at $14.1 million in 2021, then rose by 19.34% to $16.8 million in 2022, then rose by 4.10% to $17.5 million in 2023, then rose by 5.53% to $18.4 million in 2024, then rose by 8.44% to $18.3 million in 2025.
  • Its Receivables - Other was $18.3 million in Q3 2025, compared to $21.9 million in Q2 2025 and $15.4 million in Q1 2025.